NorwayNorway

New big generic

26.11.2005

Reykjavik - Actavis Group, an international generic pharmaceuticals company operating from Iceland, is to acquire US-based Alpharma generic pharmaceuticals business for $810 million. The move will solidify Actavis' entry into the US generics market and comes shortly after the company's $600-million acquisition of Amide Pharmaceutical Inc., a private US generics company.
As a combined company Actavis seeks to be among the five largest players in generic pharmaceuticals worldwide. It will have more than 600 marketed products, as well as around 10,000 employees in 32 countries. Actavis expects to benefit from Alpharma's products that can be marketed in Actavis' existing markets and vice versa. The companys revenue in 2004 was Euro 452 million.

NorwayNorway

05.04.2011

Oslo – Norwegian Algeta ASA has entered a research collaboration with Genzyme to evaluate the potential of its Thorium platform Under the terms of the agreement, Genzyme will provide access to a novel tumour-targeting antibody,...

NorwayNorway

05.04.2011

Trondheim – Norway-based APIM Therapeutics AS has received a follow-up investment from Sarsia Seed, one of its previous investors. APIM focusses on novel drug candidates that potentiate the action of current chemo­therapeutics to...

NorwayNorway

04.11.2010

Oslo – Norwegian diagnostic specialist DiaGenic ASA has raised NOK70m (EUR 8.5m) through the sale of 140 million shares at NOK0.50 per share in a private placement to new and existing investors. DnB NOR Markets acted as manager...

NorwayNorway

03.11.2010

Oslo – The Oslo Cancer Cluster and the Shanghai Institute of Materia Medica (SIMM), have signed a memorandum of understanding aimed at accelerating the development and adoption of new cancer therapies. Overall, the collaboration...

NorwayNorway

18.09.2010

Oslo/Berlin – Algeta is cashing in on its lead product Alpharadin, a targeted alpha-radiopharmaceutical in clinical trials for treating bone metastases in cancer patients. Bayer Schering Pharma has agreed to pay the Norwegian...

NorwayNorway

11.07.2010

Lysaker – Norwegian biopharmaceutical company PCI Biotech Holding ASA has strengthened the company’s equity by a11m (NOK90m) through a share issue of 2.25 million shares with preemptive subscription rights for existing...

Displaying results 11 to 20 out of 92

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/browse/1/article/new-big-generic.html

Product of the week

Products

Events

All Events

Current issue

All issues